SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix
SERB Pharmaceuticals has finalized its acquisition of development and commercialization rights to Idefirix (imlifidase) across Europe and MENA.
SERB Pharmaceuticals completed the acquisition of European and MENA development and commercialization rights to Idefirix (imlifidase) from Hansa Biopharma, the company announced Monday, marking a significant expansion of its specialty pharmaceutical portfolio in those regions.
Idefirix, known generically as imlifidase, is a targeted enzyme therapy developed to desensitize highly sensitized kidney transplant patients — a population that often faces severely limited donor compatibility options. The drug's approval in Europe represented a meaningful advance for transplant medicine, and SERB's takeover of regional rights positions the company to drive its commercial rollout more aggressively across both European and Middle East and North Africa markets.
Read more Russia Threatens Apple With $52M Fine Over App Bias →
The deal transfers full responsibility for the drug's ongoing development activities and commercial strategy in those territories from Hansa Biopharma to SERB, a specialty pharmaceutical firm focused on critical and rare disease treatments. While financial terms of the transaction were not disclosed, the completion of the acquisition signals SERB's intent to deepen its presence in the rare disease and transplant medicine space.
For Hansa Biopharma, divesting the regional rights allows the Swedish biotech to refocus its resources, potentially concentrating on other pipeline programs or geographies where it retains control. For SERB, gaining an already-approved asset with an established regulatory footprint in Europe reduces time-to-market risk compared with early-stage development investments.
The transaction underscores a broader trend of specialty pharma companies acquiring commercialization rights to approved rare-disease drugs in targeted geographies, using existing regulatory approvals as a springboard for near-term revenue generation. Continue reading at GlobalNewswire.
